FEB 16, 2018 07:00 AM PST

Clinical Trial for Cannabidiol Effect on Hyperphagia in Affected Individuals with Prader-Willi Syndrome

Photo Source: healthworxcbd.com

There is a Phase II randomized, double-blind clinical trial in the United States currently recruiting patients with Prader-Willi Syndrome (PWS) to evaluate the efficacy of cannabidiol (liquid form) use on hyperphagia (overeating) related behavior. Cannabidiol (CBD) is an agonist for receptors in the human Endocannabinoid System (ECS). INSYS Therapeutics Inc. is the sponsor of the trial which is set to start March 2018 and run through May 2018 according to the National Institutes of Health US Library of Medicine where clinical trials are documented.

Prader-Willi syndrome is a complex human genetic condition related to genomic imprinting on the acrocentric chromosome 15, specifically locus 15q11.2 region. This region is in the proximal arm of chromosome 15 right below the centromere. Imprinting is a complicated and not wholly understood genetic process whereby gene expression is regulated through epigenetic silencing (typically by methylation). The etiology of the disorder is the failure of expression of the gene located within 15q11.2 on the paternally inherited chromosome 15. The typical resulting phenotype begins in infancy with weak muscle tone, feeding difficulties, and developmental delay; successive appetite increases beginning in early childhood and by age 8 result in children with PWS having an insatiable appetite and an uncontrollable focus on food. Weight management and obesity are consistent challenges due to hyperphagia. Prader-Willi syndrome (PWS) results from three basic causes: (1) the deletion of the 15q12 region on the paternally inherited chromosome. This is likely and most often due to random events during the formation of sperm or early in fetal development; (2) the random inheritance of two copies of the mother’s chromosome 15’s, defined as an example of uniparental disomy. The medical terminology can be broken down into parts which results in: “Uni-“ = one/single, “parental” = parent, “di-” = two [copies], “somy” = [relating to] chromosomes; (3) Inheritance occurred normally but there was a defect in the imprinting process in the 15q11.2 chromosomal region.

Photo Source: University of Floria Department of Pediatrics

The human ECS plays a regulatory role in endocrine and metabolic functions, along with the central nervous system, for appetite control, food intake, and energy balance. A 2011 study in the journal of Pharmacology and Biochemical Behavior found that CBD can act as an agonist for CB1R by blocking the uptake of the human endocannabinoid molecule anandamide. There are multiple systems collaborating for food intake control including both the cannabinoid and serotinergic pathways. Williams and Kirkham (2002) published research focused on the role of SR141716A (rimonabant), a CB1R antagonist, which was shown to reverse the hyperphagic effect caused by the phytocannabinoid delta-9 tetrahydrocannabinol (THC). Rimonabant suppresses food intake signaling; CBD is an alternative cannabinoid that has similar antagonistic effects as rimonabant though may target different receptors than CB1R. CBD on its own may not change food intake but may prevent or disrupt the physiological process leading to hyperphagia.

Sources: Pharmacology, Biochemistry and Behavior (2011); Pharmacology, Biochemistry and Behavior(2002)National Institutes of Health International Conference on HyperphagiaNational Institutes of Health US Library of Medicine

About the Author
  • Mauri S. Brueggeman is a Medical Laboratory Scientist and Educator with a background in Cytogenetics and a Masters in Education from the University of Minnesota. She has worked in the clinical laboratory, taught at the University of Minnesota, and been in post secondary healthcare education administration. She is passionate about advances and leadership in science, medicine, and education.
You May Also Like
SEP 19, 2019
Cannabis Sciences
SEP 19, 2019
The Science Behind Hemp
With the signing of the latest farm bill, President Trump has just legalized the cultivation of hemp. The idea behind this legislation was to boost agricul...
SEP 19, 2019
Cannabis Sciences
SEP 19, 2019
Can Marijuana Cause Schizophrenia?
We have discussed in this newsletter about how marijuana, in some people, can cause psychosis. This usually occurs with a very potent strain of cannabis (&...
SEP 19, 2019
Cannabis Sciences
SEP 19, 2019
Marijuana Science: Who Should We Listen To?
As the US government has started to loosen its attitude towards cannabis, the field of cannabis research has become to blossom. A recent search on "ma...
SEP 19, 2019
Cancer
SEP 19, 2019
Cancer Patients Increase Cannabis Use 118 Percent in Nine Years
Between 2005 and 2014, cancer patients increased their use of marijuana/ cannabis 114 percent, according to a new study from researchers at the University ...
SEP 19, 2019
Cannabis Sciences
SEP 19, 2019
Growing up high: new insights into how cannabis changes the adolescent brain
During adolescence, important cognitive functions develop. Adolescence is a highly sensitive period for brain development as it represents a time when regions of the frontal cortex in charge...
SEP 19, 2019
Health & Medicine
SEP 19, 2019
The Science Behind Good Cannabis
The two main chemical components of the cannabis plant are Tetrahydrocannabinol and Cannabidiol. Tetrahydrocannabinol (THC) is the primary psychoactive com...
Loading Comments...